Starpharma (ASX: SPL), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, today presented its Chair’s address and CEO’s presentation at its Annual General Meeting in Melbourne. Rob Thomas AO announced his retirement as Chair after 12 years, with Dr Russell Basser proposed as his successor, pending shareholder approval. The company underscored a refined strategic focus on targeted oncology, particularly radiopharmaceuticals, to improve health outcomes for patients with significant illnesses such as cancer.
TheThe company’s updated strategy concentrates capital deployment on high-value targeted oncology opportunities where its proprietary DEP® dendrimer technology can deliver clear differentiation. A major priority is the advancement of DEP® HER2-Lu, its lead proprietary radiopharmaceutical candidate, towards clinical development. A first-in-human Phase 1 study is expected to commence in December 2026, subject to ethics approval, following encouraging preclinical results. Additionally, Starpharma increased its majority ownership in Petalion Therapeutics, accelerating a FAP-targeted oncology program which holds potential across multiple cancer types.
Strategic partnerships continue to be a cornerstone of Starpharma’s strategy, offering external validation and diverse revenue pathways. A significant achievement was the Collaboration and License Agreement with Genentech, which included an A$8.3 million upfront payment and potential milestones up to A$804 million, alongside tiered royalties. The company also secured a research and option agreement with Radiopharm Theranostics. Financially, Starpharma successfully completed a A$30 million net rights offer, reflecting strong shareholder support and extending its funding runway into fiscal year 2028, thereby bolstering its priority oncology programs. Marketed products like Viraleze and VivaGel BV further contribute to revenue.
